JNJ - Johnson & Johnson
138.76 0.00 (0.00%)
After hours: 4:52PM EDT
| Previous Close | 138.12 |
| Open | 138.35 |
| Bid | 138.73 x 1000 |
| Ask | 138.99 x 900 |
| Day's Range | 137.49 - 138.95 |
| 52 Week Range | 118.62 - 148.99 |
| Volume | 5,084,219 |
| Avg. Volume | 6,196,504 |
| Market Cap | 368.416B |
| Beta (3Y Monthly) | 0.68 |
| PE Ratio (TTM) | 25.72 |
| EPS (TTM) | 5.40 |
| Earnings Date | Jul 16, 2019 |
| Forward Dividend & Yield | 3.80 (2.69%) |
| Ex-Dividend Date | 2019-05-24 |
| 1y Target Est | 148.12 |
- Zacks•5 hours ago
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $138.76, moving +0.46% from the previous trading session.
- Reuters•8 hours ago
Congo wants more use of Merck vaccine rather than J&J newcomer - minister
Democratic Republic of Congo called on Wednesday for Merck's experimental Ebola vaccine to be fully licensed to facilitate its use in the Ebola-hit country, while saying Johnson & Johnson's rival drug would complicate matters. Both vaccines are experimental drugs that can be used under strictly controlled research protocols but Merck's has been used throughout the outbreak and has proven highly effective, the World Health Organization (WHO) says. Congolese Health Minister Oly Ilunga Kalenga told reporters in Geneva that the government would roll out a "geographic ring" vaccination strategy in the coming days.
- Benzinga•15 hours ago
The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...
- American City Business Journals•yesterday
West Chester company to eliminate 76 jobs
Medical Device company DePuy Synthes is eliminating 76 jobs in Chester County. A Worker Adjustment and Retraining Notification Act notice the orthopedic and neurosurgery products developer filed last week with the Pennsylvania Department of Labor and Industry stated its DePuy Synthes Sales Inc. unit will be eliminating its extremities sales organization in West Chester. Asked about the job reduction, DePuy Synthes issued a statment that read: "DePuy Synthes recently made a strategic decision to move away from a dedicated extremities sales force as part of an ongoing assessment of resource utilization and optimization, resulting in an overall reduction in positions.
- Zacks•2 days ago
The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
- Zacks Small Cap Research•2 days ago
ARWR: ARO-AAT Ph 2/3 Detailed, Could Serve as FDA Pivotal Study. Continued Broad-Based Pipeline Progress
This includes presentations at the EASL International Liver Congress in April from preclinical long-term data from the previous-generation AAT as well as interim results of JNJ-3989 (ARO-HBV) among 40 patients at 24+ weeks follow-up in their ongoing Phase 1/2 study. The JNJ-3989 Phase 1/2 study (chronic hepatitis B) continues and was recently expanded to include a triple combination cohort (cohort 12), which along with JNJ-3989, will include additional undisclosed agents chosen by Janssen. Management indicated that this triple combination cohort could generate data relatively quickly – which will be one of several near-term development-related announcements that we anticipate.
- Zacks•2 days ago
Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
- MarketWatch•2 days ago
Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
- Zacks•3 days ago
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
- Zacks•3 days ago
AbbVie's Brain Cancer Candidate Fails in Phase III Study
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
- American City Business Journals•3 days ago
After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm
With the launch of his new company, Miraki Innovation, Velis hopes to expand his reach in medtech, founding more companies in healthcare diagnostics, infectious disease and robotics that will follow Auris’ lead.
- Reuters•4 days ago
Modi’s jobs deficit - J&J’s largest India plant idle three years after completion
PENJERLA/NEW DELHI, India (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.
- Reuters•4 days ago
Modi’s jobs deficit: J&J’s largest India plant idle 3 years after completion
PENJERLA/NEW DELHI, India May 19 (Reuters) - It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India. Two sources familiar with J&J's operations in India and one state government official told Reuters production at the plant, at Penjerla in Telangana state, never began because of a slowing in the growth in demand for the products.
- Benzinga•4 days ago
Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More
Benzinga has examined prospects for many investor favorite stocks over the past week. Bearish calls included biotechs and a recent IPO. Furthermore, investors also saw mixed economic numbers, as well as positive surprises in quarterly reports and initial public offerings, bad news for a market darling from the Supreme Court, and fresh news for whale watchers.
- Motley Fool•4 days ago
6 Things Johnson & Johnson Wants You to Know About Its Pharmaceuticals
Here's what management wants investors to know about the future of the company's pharmaceutical segment.
- Investor's Business Daily•5 days ago
Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout
Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.
- Reuters•5 days ago
Exclusive: FBI targets Johnson & Johnson, Siemens, GE, Philips in Brazil graft case - Sources
The U.S. FBI is investigating corporate giants Johnson & Johnson, Siemens AG, General Electric Co and Philips for allegedly paying kickbacks as part of a scheme involving medical equipment sales in Brazil, two Brazilian investigators have told Reuters. Brazilian prosecutors suspect the companies channelled illegal payoffs to government officials to secure contracts with public health programs across the South American country over the past two decades. Brazilian authorities say more than 20 companies may have been part of a "cartel" that paid bribes and charged the government inflated prices for medical gear such as magnetic resonance imaging machines and prosthetics.
Reuters•5 days agoExclusive: FBI targets Johnson & Johnson, Siemens, GE, Philips in Brazil graft case - sources
The U.S. FBI is investigating corporate giants Johnson & Johnson, Siemens AG, General Electric Co and Philips for allegedly paying kickbacks as part of a scheme involving medical equipment sales in Brazil, two Brazilian investigators have told Reuters. Brazilian prosecutors suspect the companies channeled illegal payoffs to government officials to secure contracts with public health programs across the South American country over the past two decades. Brazilian authorities say more than 20 companies may have been part of a "cartel" that paid bribes and charged the government inflated prices for medical gear such as magnetic resonance imaging machines and prosthetics.
- Reuters•5 days ago
U.S. FDA labels J&J surgical staplers' recall as severest
The recall, initiated early April by Ethicon, covers 92,496 surgical staplers and is now labeled as "Class-1" - the strictest form of recall issued by FDA, where use of faulty devices may cause serious injury or death. J&J's Ethicon unit confirmed serious injuries to two patients, related to the use of the recalled product, the FDA said.
- CNBC•6 days ago
Your first trade for Friday, May 17
The "Fast Money" traders share their first moves for the market open.
- PR Newswire•6 days ago
Johnson & Johnson to Participate in Bernstein's 35th Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J. , May 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in Bernstein's 35 th Annual Strategic Decisions Conference on Thursday, May 30 , at the Grand Hyatt, New ...
- Zacks•6 days ago
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
- Motley Fool•6 days ago
Did Geron's Big Announcement Just Go Unnoticed?
Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
